Dr Lal PathLabs Q2 FY27 Earnings Call: Revenue Growth Hits Five-Year High, Margins Run Ahead of Plan (LALPATHLAB)

Dr Lal Pathlabs Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Best Quarterly Growth in Five Years, Margins Ahead of Plan

• Revenue of Rs.874 crore, up 19.6% YoY — the highest quarterly growth in the last five years (vs Rs.731 crore in Q2 FY 2025-26); H1 FY 2026-2027 revenue at Rs.1,672 crore, up 19.4% YoY.
• Sample volume up 13.6% to 28.8 million; patient volume up 9% to 9 million — a multi-quarter high (17-18 quarters); revenue per patient at Rs.976, up 9.7% vs Rs.889 in Q2 FY 2025-26.
• EBITDA of Rs.280 crore, up 25.1% YoY with a 32.1% margin; H1 FY 2026-2027 EBITDA at Rs.528 crore, up 26.7% YoY, at a 31.6% margin.
• PAT of Rs.194 crore, up 27.5% YoY (vs Rs.152 crore in Q2 FY 2025-26) at a 22.2% margin; H1 FY 2026-2027 PAT at Rs.364 crore, up 27.3%, at a 21.8% margin. EPS at Rs.11.5 for Q2 FY 2026-2027 (vs Rs.9 in Q2 FY 2025-26).
• Net cash of Rs.1,746 crore as of 30 September 2026; net working capital negative at 16 days (DSO 17 days, DIO 32 days). Board declared an interim dividend of 50%, i.e., Rs.5 per share.
• PBT of Rs.261 crore, up 28.1% YoY at a 29.8% margin; H1 FY 2026-2027 PBT at Rs.489 crore with a 29.3% margin.

SNG Deal Draws Valuation Scrutiny; Early Steps Abroad

• SN Gene Lab acquired for Rs.168 crore (70% stake) — CFO Ved Prakash Goel corrected the analyst's higher figure; the remaining 30% is covered by a pre-specified put and call option, with terms not yet disclosed and the timeline described as continuing "for some time."
• Valuation contested — analyst Rishi Modi estimated implied total consideration of ~Rs.220-225 crore, or ~15x EV/EBITDA on ~Rs.15 crore EBITDA; management said the figures were incorrect and invited the analyst to send valuation queries offline. Separately, Tauseef (BNP Paribas) flagged ~Rs.200 crore total consideration including Rs.31 crore of performance-linked payments, implying ~5x trailing EV/EBITDA; CEO Shankha Banerjee countered that on the EBITDA multiple the price paid is "much better" than the competitor deal referenced, calling SNG a "big strategic fit."
• SNG generated FY26 revenue of ~Rs.60 crore and EBITDA of ~Rs.15 crore per the CFO; the August (Q2 FY 2026-2027) close means Q2 FY 2026-2027 does not capture a full quarter of contribution. The company also acquired the remaining 30% stake in subsidiary Center Path Labs, making it wholly owned.
• International expansion advanced in Q2 FY 2026-2027 — acquisition of Sunshine Diagnostics in Ghana and a JV incorporated in Uzbekistan that will start on-ground operations quite soon; management characterized these as small steps toward building a meaningful long-term business.
• International is below 5% of revenues (Q2 FY 2026-2027) and management expects it to remain at that contribution level 2-3 years from now (≈FY 2028-2029 to FY 2029-2030), while believing it can become a bigger contributor over the longer term. Over the next ~5 years or so, and maybe even longer, the company aims to build know-how to run businesses in a "conglomerate fashion."
• Sovaaka remains a single-center operation under development — management is not disclosing its revenue separately and may do so only once it scales into a larger vertical.

Broad-Based Volume Gains; CGHS Tailwind Is Temporary

• Volume growth of 9.8% in patient volumes (per Q&A ~8%+ cited elsewhere) was attributed by CEO Shankha Banerjee to broad-based gains across the country plus reach build-out — lab network and collection center additions made 2-3 years ago now contributing.
• CGHS price hike contributed 2-3% to Q2 FY 2026-2027 revenue growth — effective around end of Q3/early Q4 FY 2025-2026, the benefit may persist for one more quarter (Q3 FY 2026-2027) before becoming part of routine organic growth; per management, the benefit goes away after four quarters.
• West delivered better-than-before growth and the Suburban brand is back to double-digit growth — having "turned the corner" — with on-ground brand and infrastructure investments being deployed to sustain or improve its growth rate.
• South India is ~6% of revenues — management remains in "search mode" for an inorganic opportunity; until a solid deal emerges, the organic push continues, focused on specific geographies and larger urban clusters.
• Close to 40% (39%) of revenues come from tier 3 towns and below (FY 2026-2027) — responding to a question citing Metropolis' aggressive north India tier-3 expansion, the CEO said no incremental strategy is needed and the company is gaining share under its current expansion plan.
• Competitive intensity unchanged — management said diagnostics competition has always been high and will remain high; the real competition is unorganized players, who still hold the largest share of the pie across urban markets and smaller towns.
• Rural outreach program gaining strength in seven states where it has been launched, with higher patient numbers in Q2 FY 2026-2027.

Gross Margin Streak Intact, But CFO Flags Cost Risks

• Gross margin improved 50 bps sequentially in Q2 FY 2026-2027 despite Swasthfit's contribution as a% of revenue declining; CFO Ved Prakash Goel attributed consistent improvement over the last 4 quarters to operating leverage on double-digit volume growth, favorable test mix, and cost-optimization programs.
• CFO cautioned the past gross-margin trajectory should not be assumed to continue as-is — inflationary costs (dollar moving up, geopolitical situation) may have some impact going forward.
• Other expenses stepped up from a Rs.120-125 crore quarterly run rate until Q3 FY26 to ~Rs.150 crore over the last three quarters, including Rs.164 crore in Q2 FY 2026-2027 — drivers are infrastructure expansion (32 labs opened over the last 2 years, ~15-18 labs planned in FY 2026-2027) plus inflationary costs (minimum wage changes, PF rule changes, transportation/logistics); other expenses as a% of revenue is not rising, only in absolute terms.
• No price increase taken for more than 4 years — the last hike was ~4 years ago; post-COVID the company consciously avoided hikes to keep unorganized competitors in check, and management said the pricing window "has now opened up."
• Management sees no need for price increases right away in FY 2026-2027 — CGHS pass-through benefits are helping manage costs; on a longer-term CAGR basis, any future increases will be kept below inflation so unorganized competition does not get headroom to match increases.
• Pricing triggers and timing — management ruled out hiking merely to lift revenue growth; stated triggers are cost pressures becoming difficult to absorb (dollar movement, PF/gratuity regulatory notices) or movement in the overall market pricing table. Timing and quantum will be re-examined over the next 1-2 quarters (Q3-Q4 FY 2026-2027); management did not commit to the 2-3% portfolio-level hike floated in the question.

High-Teens FY27 Growth; FY28-29 Question Deferred

• Management is looking at possibly high-teen revenue growth for FY 2026-2027 — FY27 numbers are ahead of expectations, with H1 FY27 tracking slightly ahead of plan.
• FY 2026-2027 EBITDA margin should come in slightly better than FY 2025-2026's 28.3% — CEO Shankha Banerjee declined to raise the earlier 27-28% FY 2026-2027 guidance, framing the full-year outcome against the FY 2025-2026 actual.
• FY28 (FY 2027-2028) planning has not yet begun — on whether the mid-teens FY28-29 revenue growth guidance would hold if Q3-Q4 FY 2026-2027 growth normalizes due to the CGHS base effect, the CEO said a directional answer may come 1-2 quarters down the road (around Q3-Q4 FY 2026-2027).
• Long-term growth algorithm (period unspecified) — management expects patient volume growth of 6-7% plus, potentially, another 6-7% from price/realization (geography and mix benefits), and feels mid-teens organic revenue growth is sustainable over the longer term.
• Margins running ahead of expectations in H1 FY 2026-2027 — management may reinvest the surplus and fast-track planned investments into the business in H2 FY 2026-2027 to sustain the revenue growth trajectory; the CEO corrected that he had not referenced any "held investments."
• Cash deployment under internal review — management said it has internal thoughts on deployment, including evaluating decent-sized M&A deals to gain platform positions in certain geographies; details will be shared when ready. Acquiring assets outside India remains on the table.
• Newer initiatives positioned as long-term, not near-term — Sovaaka International and radiology (not GeneLab) are viewed as long-term growth drivers rather than contributors over the next 2-3 years (i.e., not within FY 2027-2028 through ~FY 2029-2030). The two pilot radiology centers are a patient-service play for core markets like Delhi NCR, not a standalone ROI play.

Unorganized-to-Organized Shift and Public Health Tailwinds

• Management cited the government's NP-NCD program — through 1.8 lakh Ayushman Arogya Mandirs, 41.5 crore people screened for hypertension, 41.3 crore for diabetes, 35.3 crore for oral cancer, 16.5 crore women for breast cancer, and 8.7 crore women for cervical cancer; management noted screening is only the start of the clinical journey, so the need for accurate, accredited, high-quality confirmatory diagnostics will only increase.
• Unorganized-to-organized migration reiterated as the defining opportunity of this decade — to be won on quality, reach, and trust; management said holding prices longer supports this shift, which is visible in current volume flows.
• ~140 new tests launched during H1 FY27, including two first-in-India assays in Q2 FY27, focused on oncogenomics, transplant immunology, and rare genetic disorders; the SNG acquisition adds differentiated tests in oncogenomics and reproductive genomics with active genomics R&D and international tie-ups.
• Specialized test menu growing well — supporting differentiation, client entry, and realizations (these tests carry higher pricing); management views the current routine-vs-specialized mix as appropriate and does not expect the specialized contribution to keep rising.
• Digital and patient-experience investments — a new physical patient report format with trend charts and anti-counterfeit watermark now reaches more than 80% of patients daily; an enterprise-wide digital pathology foundation on a hybrid cloud platform is future-ready for multiple business streams including AI-led services.